drugset
drugset / Trial / NCT04445090

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood

NCT04445090 ↗

Phase 1 Terminated 68 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

SRD-Part: To investigate safety, tolerability, pharmacokinetics and pharmacodynamics following single rising doses (SRD) of BI 1569912 BA/FE-Part: To investigate (a) the relative bioavailability (BA) of BI 1569912 and (b) the influence of food (FE) on the relative bioavailability of BI 1569912

Timeline

Start
2020-07-21
Primary completion
2021-09-10
Completion
2021-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1569912 Unknown 0.25 mg Oral
Subject BI 1569912 Unknown 0.75 mg Oral
Subject BI 1569912 Unknown 2 mg Oral
Subject BI 1569912 Unknown 5 mg Oral
Subject BI 1569912 Unknown 10 mg Oral
Subject BI 1569912 Unknown 20 mg Oral
Subject BI 1569912 Unknown 30 mg Oral

Indications

No indication recorded.